NovImmune raises CHF 62.5 million in private placement

Country

Switzerland

NovImmune SA of Switzerland has raised CHF 62.5 million in a private share placement with existing and new investors. The proceeds will be used to take control of two therapeutic monoclonal antibodies previously licensed to Merck Serono.

---Subscribe to MedNous to access this article---